Company intelligence / Profile preview

Hope Biosciences

Sugar Land, Texas, United Stateshope.bio ↗

Ownership: Private
Development stage: Phase 2

Overview

As of 2023, Hope Biosciences cultured approximately 170 billion adult stem cells for use in dozens of disease and injury conditions, including in 18 FDA-authorized research protocols. Their autologous adipose derived mesenchymal stem cells (HB-adMSCs) were authorized for use in a rare form of pediatric drug-resistant epilepsy.

Therapeutic areas: RheumatologyEndocrinologyImmunologyOncologyNeurologyInfectious Diseases
Modalities: Mesenchymal stem cells (MSCs)Adult stem cell therapeuticsAutologous adipose derived mesenchymal stem cells (HB-adMSCs)
Industry: Biotech

Drug pipeline

8 assets

HB-adMSC

Approved

7 more assets in the full pipeline.

Partnerships

Academic and clinical research organizationsGreater Houston Community Foundation (administers the Hope Biosciences Stem Cell Research Foundation)

Beyond the preview

Go deeper on Hope Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hope Biosciences.